Nestle Health Science enters microbiome research venture

929c1134-8d44-4139-8110-035684bd4b33articleimage.jpg

13 Jul 2017 --- Nestlé Health Science and Enterome are establishing Microbiome Diagnostics Partners (MDP), in an attempt to lead the development and commercialization of innovative microbiome-based diagnostics with the potential to transform therapeutic approaches across health conditions such as inflammatory bowel diseases (IBD) and liver diseases. The partnership follows Nestlé Health Science’s initial investment announced in April 2016.

“Mastering the microbiome is an important facet of our strategy to advance the therapeutic role of nutrition. We also see new opportunities for personalized nutrition both for the healthy population and for patients. The two initial programs have great potential to become differentiated diagnostics,” says Greg Behar, CEO of Nestlé Health Science.

According to the companies, MDP will initially aim to boost Enterome’s diagnostic programs, which include IBD 110 for the assessment and management of mucosal healing and MET210 for NASH (non-alcoholic steatohepatitis). The current standard of care for these conditions include invasive procedures such as endoscopy and biopsies, rather than a non-invasive stool/serum combined Dx tests that will be developed by MDP. Future innovation efforts will leverage advanced microbial and serum-based metabolic technologies developed respectively at Enterome and Nestlé Health Science’s diagnostics arm Prometheus Laboratories.

The companies announced that Microbiome Diagnostics Partners is to be a 50:50 joint venture between Enterome and Nestlé Health Science. Prometheus (a Nestlé Health Science Company) will contribute its Diagnostics (Dx) development and commercialization expertise. Enterome will contribute its current microbiome diagnostic programs and intellectual property (IP) derived from its unique microbiome-based platform for the development of Dx in all therapeutic areas except immuno-oncology. 

Nestlé Health Science will reportedly invest €20 million in return for its 50 percent stake in MDP and exclusive commercialization options on the initial programs. In addition to this investment, MDP will receive further milestone payments linked to the success of clinical and commercial activities.

Commenting on the move, Behar says, “Microbiome Diagnostics Partners is equipped to lead diagnostic discovery in the microbiome field, opening the door to innovative therapeutic approaches combining diagnostics (Dx), nutritional therapies (Nx) and therapeutics (Rx).” 

“The formation of Microbiome Diagnostics Partners is an important milestone for Enterome, as it brings together powerful and complementary technologies and capabilities to enable the creation of a new generation of diagnostic and companion diagnostic products. The MDP joint venture will leverage Enterome’s microbiome-based platforms in diagnostic areas, while Enterome will continue to focus on their application for the discovery of novel small molecule therapeutics,” comments Pierre Belichard, CEO of Enterome.

Related Articles

Nutrition & Health News

What happens in the gut after too much fructose? Mouse study sheds light on role of small intestine

07 Feb 2018 --- In mice, fructose is processed mainly in the small intestine, not in the liver as had previously been suspected, Princeton University researchers report. However, sugary drinks and processed high-sugar foods may overwhelm the small intestine and spill into the liver for processing. Additionally, the authors note that the ability of the small intestine to process fructose is higher after a meal. Although the study was conducted in mice, the researchers recommend "the most old-fashioned advice in the world" for humans: Limit sweets to moderate quantities after meals, and do not have sweet drinks away from meal time.

Nutrition & Health News

Superfoods: Fermented foods tipped as top 2018 trend by dieticians

08 Jan 2018 --- Fermented foods – such as yogurt, kefir, kombucha and sauerkraut – are to be the no. 1 superfood for 2018, underlining that consumers will be “going with their gut” in the coming year by seeking out foods that improve gut health and overall well-being. This is according to the Pollock Communications and Today's Dietitian's "What's Trending in Nutrition" national survey which gauges the opinions of 2,050 registered dietitian nutritionists (RDNs) on what consumers are thinking and eating. 

Nutrition & Health News

DSM expands gut health ingredients portfolio with acquisition of BioCare Copenhagen

02 Jan 2018 --- Royal DSM has acquired BioCare Copenhagen A/S to expand its offering in gut health ingredients with probiotics, an attractive market segment in nutritional ingredients, growing an estimated 7 percent per year. Financial details will not be disclosed at this time.

Nutrition & Health News

Gut microbiota: Transient effects found for a preservative

19 Dec 2017 --- Antimicrobial compounds added to preserve food during storage are believed to be benign and non-toxic to the consumer, but there is "a critical scientific gap in understanding the potential interactions" they may have with the hundreds of species of microbes in our intestines, say David Sela, a nutritional microbiologist at the University of Massachusetts Amherst, and colleagues.

Business News

Seventure Partners’ microbiome portfolio nears critical milestones 

18 Dec 2017 --- Seventure Partners, one of Europe’s leaders in financing innovation, and a world-leader in the venture investment in the microbiome sector, is seeing rapid progress from innovation into human trials, with five of its portfolio companies advancing their human microbiome products with varying modalities and therapeutics targets in clinical trials.

More Articles
URL : http://www.nutritioninsight.com:80/news/nestle-health-science-enters-microbiome-research-venture.html